Candid Therapeutics

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

BHP explores a potential $2 billion sale of Chilean desalination and electricity transmission assets supporting its major copper operations. Representative image.

BHP (ASX: BHP) explores $1.5-$2bn sale of Chilean desalination plant and power lines

Vodafone shares surge after Xavier Niel’s Vega agrees to acquire e&’s 16.21 percent stake in a £4.4 billion transaction. Representative image.

Vodafone (LSE: VOD) jumps 12% as Xavier Niel’s Vega buys e&’s 16.21% stake for £4.4bn

GlobalWafers and Micron Technology expand United States semiconductor supply capacity through a $500 million financing and 10-year silicon wafer agreement. Representative image.

GlobalWafers locks in $500m Micron financing and 10-year Sherman wafer supply pact

Ukraine’s new long-range strike command intensifies its campaign against Russian oil refineries, fuel infrastructure and wartime logistics networks. Representative image.

Ukraine’s drone war enters new phase with dedicated command targeting Russia

Candid Therapeutics launches first-in-class T-cell engager trials across five autoimmune diseases

Candid Therapeutics begins Phase 1 trials of BCMA and CD20 T-cell engagers across five autoimmune diseases; institutional interest builds around TCE approach.

μFR system
αvβ6-integrin
α4β7 integrin
Zywie Ventures
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures

June 24, 2025